- Home
- NUAI vs CRBP Comparison
NUAI vs CRBP Comparison
Compare NUAI & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUAI | CRBP |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.3M | 170.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NUAI | CRBP |
|---|---|---|
| Price | $4.61 | $7.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $50.29 |
| AVG Volume (30 Days) | ★ 7.5M | 162.1K |
| Earning Date | 03-31-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $843,029.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $220.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 50.89 | N/A |
| 52 Week Low | $0.32 | $4.64 |
| 52 Week High | $9.45 | $20.56 |
Technical Indicators
Market Signals| Indicator | NUAI | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 43.15 | 41.61 |
| Support Level | $4.78 | $7.33 |
| Resistance Level | $5.39 | $8.23 |
| Average True Range (ATR) | 1.00 | 0.59 |
| MACD | -0.30 | -0.04 |
| Stochastic Oscillator | 0.26 | 22.94 |
Price Performance
Historical ComparisonAbout NUAI New Era Energy & Digital Inc.
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.